RNA vaccines

French pharmaceutical giant Sanofi has struck a deal with newly launched biotech ScionxBio to develop long-acting RNA medicines, according to an exclusive report by Endpoints News. The tie-up signals Sanofi's continued push into RNA-based therapeutics, a field energised by the success of mRNA vaccines. Details of the financial terms and ScionxBio's technology have not yet been disclosed.